Bilateral Poorly Differentiated Adenocarcinoma of the Lacrimal Gland with Tumor Regression after Treatment with Pembrolizumab

Ann Q. Tran, Catherine J. Choi, Zakeya Al-Sadah, Xiao Yi Zhou, Sander Dubovy, Neal E. Rothschild, Bradford W. Lee

Research output: Contribution to journalArticlepeer-review

Abstract

An 85-year-old man presented with a 6-month history of worsening left proptosis and painless ophthalmoplegia. Imaging revealed an extensive intraconal and extraconal tumor extending to the level of the optic foramen, as well as the scalp, cheek, and the nasal bridge. Incisional biopsy was consistent with lacrimal gland adenocarcinoma. The patient underwent a left orbital exenteration followed by immunotherapy with pembrolizumab. The treatment was stopped prematurely after 5 cycles due to development of autoimmune colitis. Four months later, the patient developed new contralateral disease in the right orbit and an incisional biopsy again showed lacrimal gland adenocarcinoma. Following the incisional biopsy, no further treatment was administered, but over the ensuing 6 months, there was dramatic spontaneous regression of the tumor both clinically and radiographically. At 28 months, the patient is still alive with relatively stable disease.

Original languageEnglish (US)
Pages (from-to)E144-E147
JournalOphthalmic plastic and reconstructive surgery
DOIs
StateAccepted/In press - 2020

ASJC Scopus subject areas

  • Surgery
  • Ophthalmology

Fingerprint Dive into the research topics of 'Bilateral Poorly Differentiated Adenocarcinoma of the Lacrimal Gland with Tumor Regression after Treatment with Pembrolizumab'. Together they form a unique fingerprint.

Cite this